CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Key facts

Sponsor

Wake Forest University Health Sciences

Principal Investigator

Caio Rocha Lima, MD

Wake Forest University Health Sciences

Intervention

6,8-bis(benzylthio)octanoic acid(drug)

Enrollment

17 enrolled

Eligibility

18 years · All sexes

Timeline

2013 – 2018

Study locations (1)

• Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07265674
  A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
  J-Pharma Co., Ltd.
• RECRUITINGPHASE3NCT06282575
  Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
  Jazz Pharmaceuticals
• RECRUITINGNCT07007832
  Bile Omics for Diagnosing Indeterminate Biliary Strictures
  Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
• ACTIVE NOT RECRUITINGPHASE1NCT03257761
  Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
  University of Southern California

See all trials for Adenocarcinoma of the gallbladder and extrahepatic biliary tract →